Drug intelligence / Profile preview

GTN040

Development stage: Preclinical
Lead developer: Keio University
Modality: Small Molecules
Administration: Oral

Overview

GTN040 is a small molecule derivative of Komaroviquinone (KQN) being investigated for its ability to induce immunogenic cell death (ICD) in multiple myeloma cells. It promotes the cell surface expression of calreticulin (CRT) and the release of damage-associated molecular patterns (DAMPs) such as ATP and HMGB1. These processes lead to the maturation of dendritic cells, characterized by increased expression of HLA-DR, CD80, and CD83, potentially enhancing the efficacy of cancer immunotherapies. The compound was identified through screening a library of GTN compounds by researchers at Keio University and the National Cancer Center Research Institute in Japan.

Other names: Komaroviquinone-derived compound

Targets

HMGB1 (High mobility group protein B1)CALR (Calreticulin)

Beyond the preview

Go deeper on GTN040.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GTN040.

Explore the full profile